Introduction
The number of cancer survivors continues to grow in the United States despite
overall declining incidence rates in men and stable rates in women.1 This reflects
an increasing number of new cancer diagnoses resulting from a growing and aging
population, as well as increases in cancer survival because of advances in early
detection and treatment.
The American Cancer Society collaborates with the National Cancer Institute
biennially to estimate the numbers of current and future cancer survivors to help
the public health community better serve this unique population, some of whom
must cope with long-term physical effects of treatment, as well as psychological
and socioeconomic sequelae.2 In this article, we use the term cancer survivor to
describe any person who has been diagnosed with cancer, from the time of diagnosis through the remainder of his or her life. This includes patients currently undergoing treatment and those who may have become cancer-free. Throughout this
article, the terms cancer patient and survivor are used interchangeably,
although not all people with a history of cancer identify with the term cancer
survivor. We provide estimates for the most prevalent cancers, as well as statistics
on treatment patterns and survival and issues related to survivorship.
271
Stage at Diagnosis
Several different staging systems are used to classify cancers. In this report, the American Joint Committee on
Cancer staging system,8,9 which is commonly used in clinical settings, is used for the description of treatment patterns; whereas SEER Summary Stage, a staging system
frequently used by population-based cancer registries, is
used to describe population-based patterns of stage at
diagnosis and survival.
survival, which adjusts for normal life expectancy by comparing survival among cancer patients with that of the general
population, controlling for age, race, and sex. The SEER 18
registries were the source for 5-year survival (diagnosis years
2005-2011). Data from the 9 oldest SEER registries are
used to describe changes in survival over time. Many of these
statistics were originally published in the SEER Cancer
Statistics Review, 1975-2012.10 In addition, 1-year, 10-year,
and 15-year relative survival rates were generated for selected
sites using the National Cancer Institutes SEER*Stat software (version 8.2.1).11,12 One-year survival rates are based on
cancer patients diagnosed from 2008 to 2011, 10-year survival rates are based on diagnoses from 1999 and 2011, and
15-year survival rates are based on diagnoses from 1994 and
2011; all patients were followed through 2012.
Treatment
Cancer treatment data were analyzed from 2 sources: the
National Cancer Data Base (NCDB) and the SEER program.
NCDB
The NCDB is a hospital-based cancer registry jointly sponsored by the American Cancer Society and the American
College of Surgeons. It includes approximately 70% of all
invasive cancers in the United States from more than 1500
facilities accredited by the American College of Surgeons
Commission on Cancer (CoC).13,14 Studies have shown
that disease severity and treatment patterns in the NCDB
stratified by clinical and sociodemographic factors for common cancer types are remarkably similar to those found in
population-based registries.15,16
Treatment data are for cases diagnosed in the first 6
months of 2013 for all sites except testis, for which aggregated data from 2009 through 2013 were used because of
the relatively small number of cases. In the 2013 NCDB
data release, many common targeted therapy drugs are classified as chemotherapy. For this report, we also include
drugs classified as immunotherapy in the chemotherapy category (chemotherapy does not include hormone therapy).
For more information regarding drug classification categories, see the SEER-Rx Web site (seer.cancer.gov/tools/
seerrx). Our analysis of treatment patterns does not include
diagnostic procedures. Methods of drug delivery are not
available in the NCDB, so topical or intravesical chemotherapy cannot be distinguished from systemic chemotherapy. More information can be found on the NCDB Web
site (facs.org/cancer/ncdb).
SEER
Survival
There are 2 common measures of cancer survival: relative
survival and observed survival. In this article, we use relative
272
Selected Cancers
Breast (female)
It is estimated that there are more than 3.5 million women
living in the United States with a history of invasive breast
273
TABLE 1.
Estimated Number of US Cancer Survivors as of January 1, 2016, by Sex and Time Since Diagnosis
MALE AND FEMALE
MALE
FEMALE
YEARS SINCE
DIAGNOSIS
NO.
PERCENT
CUMULATIVE
PERCENT
NO.
PERCENT
CUMULATIVE
PERCENT
NO.
PERCENT
0 to <5 y
5 to <10 y
10 to <15 y
15 to <20 y
20 to <25 y
25 to <30 y
30 y
5,189,400
3,530,890
2,493,340
1,655,400
1,082,460
660,180
921,550
33
23
16
11
7
4
6
33
56
72
83
90
94
100
2,713,350
1,798,090
1,212,930
729,830
443,630
228,710
250,560
37
24
16
10
6
3
3
37
61
78
87
94
97
100
2,476,050
1,732,800
1,280,410
925,570
638,830
431,470
670,990
30
21
16
11
8
5
8
CUMULATIVE
PERCENT
30
52
67
79
86
92
100
Among women diagnosed with stage I or II breast cancer, 61% undergo BCS (with the majority also receiving
additional therapy) and 36% undergo mastectomy (Fig. 4).
A much smaller percentage of stage III patients undergo
BCS (21%), whereas 72% undergo mastectomy. Women
diagnosed with stage IV disease most often receive radiation and/or chemotherapy alone (48%). Among women
with hormone-receptor positive breast cancer of any stage,
79% receive hormonal therapy.14
Breast reconstruction for women who undergo mastectomy may involve the use of a saline or silicone implant, a tissue flap, or a combination thereof. Although reported rates
of breast reconstruction in the United States vary widely, a
recent large study found that the 57% of women with nonmetastatic disease who received mastectomies underwent
reconstructive procedures.21 Women who undergo bilateral
mastectomy, are unmarried, or who have higher education or
income are more likely to undergo reconstruction.22
The overall 5-year relative survival rate for female
patients with breast cancer has improved in the past 3 deca-
TABLE 2.
Estimated Number of US Cancer Survivors as of January 1, 2016, by Sex and Age at Prevalance
MALE AND FEMALE
All Ages, y
014
1519
2029
3039
4049
5059
6069
7079
80
des, because of improvements in treatment (ie, chemotherapy, hormone therapy, and targeted drugs) and earlier
detection through increased awareness and widespread use
of mammography.23 The 5-year, 10-year, and 15-year relative survival rates for breast cancer are 89%, 83%, and 78%,
respectively.
Cancer-related factors that influence survival include
stage, tumor grade and histology, hormone receptor status,
and human epidermal growth factor receptor 2 (HER2)
status. Sixty-one percent of breast cancers are diagnosed at
a localized stage, for which the 5-year relative survival rate
is 99%. However, compared with white women, black
women are less likely to be diagnosed with local stage breast
cancer (53% vs 62%) and have lower survival within each
stage.10 These differences are driven in part by socioeconomic factors and differences in comorbidities, less access
to and use of high-quality medical care among black
women, and biological differences in cancers (eg, higher
incidence of triple negative cancers among black
women).2426
MALE
FEMALE
NO.
PERCENT
CUMULATIVE
PERCENT
NO.
PERCENT
CUMULATIVE
PERCENT
NO.
PERCENT
15,533,220
65,190
47,180
187,490
408,790
958,600
2,389,670
4,141,950
4,011,790
3,322,560
<1
<1
1
3
6
15
27
26
21
<1
1
2
5
11
26
53
79
100
7,377,100
32,060
23,610
90,730
166,170
347,700
963,410
2,027,150
2,148,940
1,577,330
<1
<1
1
2
5
13
27
29
21
<1
1
2
4
9
22
49
79
100
8,156,120
33,130
23,570
96,760
242,620
610,900
1,426,260
2,114,800
1,862,850
1,745,230
<1
<1
1
3
7
17
26
23
21
274
CUMULATIVE
PERCENT
<1
1
2
5
12
30
56
79
100
FIGURE 2. Age Distribution of Survivors for Selected Cancer Types, January 1, 2016.
Percentages may not sum to 100% because of rounding.
275
FIGURE 3. Age Distribution of New Cases (%), Median Age at Diagnosis, Estimated Number of New Cases, and 5-year
Relative Survival by Cancer Type.
*The new case estimate includes other biliary cancers. Note that sites are ranked in order of the median age at diagnosis from oldest to youngest. Sources:
Age distribution based on 2011 to 2012 data from the North American Association of Central Cancer Registries and excludes Arkansas and Nevada. The
median age at diagnosis and 5-year relative survival are based on cases diagnosed during 2008 through 2012 and 2005 through 2011, respectively, from the
Surveillance, Epidemiology, and End Results 18 registries and were previously published in Howlader et al,10 and the 2016 estimated cases are from
Siegel et al.1
276
coordinated by a team of experts, including pediatric oncologists, surgeons and nurses, social workers, child life specialists, psychologists, and others.
Adolescents (ages 15-19 years) diagnosed with cancers
that are more common in childhood are usually most
appropriately treated at pediatric facilities or by pediatric
specialists. For example, studies have shown that pediatric
protocols result in better outcomes than adult protocols for
adolescent patients with acute lymphocytic leukemia
(ALL).41 In addition, childhood cancer centers are more
likely than adult cancer centers to offer adolescent patients
the opportunity to participate in clinical trials.42 For teen
patients with cancers that are more common among adults,
such as melanoma, testicular, and thyroid cancers, treatment
by adult-care specialists is more appropriate.43
The overall 5-year relative survival rate for all childhood
cancers (aged birth-14 years) combined has improved
markedly over the past 30 years, from 58% for patients
diagnosed between 1975 and 1977 to 83% for those diagnosed during 2005 through 2011, because of new and
improved treatments. Although there has been less dramatic
improvement in survival for adolescents, the current 5-year
relative survival rate (84%) is similar to that for children.10,44
However, survival rates vary considerably by cancer type.
For example, the 5-year survival rate during 2005 through
2011 was 89% for children and 76% for adolescents for
ALL, compared to 69% and 61%, respectively, for
osteosarcoma.10
Short-term and long-term health effects
Childhood cancer survivors may experience both long-term
(chronic) and late (occurring months or years after diagnosis or treatment) effects. Aggressive treatments used for
childhood cancers, especially in the 1970s and 1980s, have
resulted in several late effects, including increased risk of
subsequent neoplasms and cardiomyopathies. A recent
study found that 50% of childhood cancer survivors had
developed a severe or life-threatening chronic health condition by age 50 years.45 Among childhood cancer survivors
who were diagnosed and treated between 1962 and 2001,
65% of those who were exposed to pulmonary toxic cancer
treatments experienced pulmonary dysfunction, and 57% of
those who were exposed to potentially cardiotoxic therapies
experienced cardiac abnormalities.
Recent declines in late morbidity and mortality among
childhood cancer survivors are due in part to reduced use of
certain treatments, such as cranial radiation for ALL and
abdominal radiation for Wilms tumor.45 However, even
many newer, less toxic therapies increase the risk of serious
health conditions in long-term childhood cancer survivors.46
Cognitive impairment, which can vary in severity, affects up
to one-third of childhood cancer survivors.47 In addition,
surgery, radiation, and some chemotherapies affecting the
277
Neuropathy is a common side effect of chemotherapy regimens containing oxaliplatin.52 Chronic diarrhea occurs in
about one-half of colorectal cancer survivors.53 Bowel dysfunction (including increased stool frequency, incontinence,
radiation proctitis, and perianal irritation) is common among
rectal cancer survivors, especially those treated with pelvic
radiation.54,55 Survivors may also suffer from bladder dysfunction, sexual dysfunction, and negative body image.39,56,57
Referral to a trained ostomy therapist may benefit patients
with a colostomy who experience these issues.58 In addition,
cancer recurrence is not uncommon among colorectal survivors,59,60 who are also at increased risk of second primary
cancers of the colon and rectum and other cancer sites,
particularly those within the digestive system.61
AML
Chemotherapy is the standard treatment for AML,
although many older adults, among whom the disease is
most common, are not able to tolerate the most aggressive
and potentially curative protocols. Patients may also
undergo allogeneic stem cell transplantation, and some
278
279
The first course of treatment for all NHL subtypes combined is usually chemotherapy, either alone (58%) or in
combination with radiation (11%) (Fig. 7). Approximately
17% of patients receive no treatment. A monoclonal antibody like rituximab is often given along with chemotherapy
for B-cell lymphomas and for some T-cell lymphomas.
The 5-year survival rate is 86% for follicular lymphoma
and 61% for DLBCL; 10-year survival declines to 77% and
53%, respectively.
Short-term and long-term health effects
People treated for leukemia and lymphoma can experience
several significant long-term and late effects. Some leukemia and lymphoma survivors, such as those who undergo
stem cell transplantation, have problems with recurrent
infections and with anemia, which may require blood transfusions. Certain chemotherapy drugs, as well as high-dose
chemotherapy used for stem cell transplantation, can lead
to infertility. Allogeneic transplantation used to treat acute
leukemias can lead to chronic graft-versus-host disease,
which can cause skin changes, dry mucous membranes
(eyes, mouth, vagina), joint pain, weight loss, shortness of
breath, and fatigue.
Chest radiation for HL increases the risk for cardiac dysfunction as well as breast cancer among women who were
treated in childhood and adolescence. Patients with HL,
NHL, and ALL are commonly treated with anthracyclines,
which can also be cardiotoxic. In the past, some children
with ALL who were at increased risk for CNS relapse
received cranial radiation therapy. This treatment can cause
long-term cognitive deficits, and it is used less frequently
and at lower dosages today.77
2013.
Chemo indicates chemotherapy (includes immunotherapy and targeted therapy); RT, radiation therapy. Source: National Cancer Data Base, 2013.
FIGURE 8. Nonsmall Cell Lung Cancer Treatment Patterns (%) by Stage, 2013.
Chemo indicates chemotherapy (includes immunotherapy and targeted therapy); RT, radiation therapy. Source: National Cancer Data Base, 2013.
Melanoma
It is estimated that there are more than 1.2 million melanoma survivors living in the United States, and an additional 76,380 people will be diagnosed in 2016. Sixty-three
percent of melanoma survivors are under the age of 70, and
17% are under the age of 50 (Fig. 2). Melanoma incidence
rates continue to increase in men but have recently stabilized in women.1 Women tend to be diagnosed at a
younger age than men (58 vs 65 years, respectively),10
reflecting differences in occupational and recreational exposure to ultraviolet radiation, as well as early detection;
women are more likely to be diagnosed at a localized stage,
86% versus 82% of men.
Treatment and survival
Surgery is the primary treatment for most melanomas.
Patients with stage III disease may be offered adjuvant
immunotherapy with interferon or the anticytotoxic Tlymphocyte-associated protein (anti-CTLA) antibody ipilimumab, although these treatments can have serious side
effects. Treatment for patients with stage IV melanoma has
changed in recent years and typically includes immunotherapy (ipilimumab, pembrolizumab, and nivolumab) or targeted therapy drugs, both of which have been shown to
extend survival.8284 BRAF (B-Raf proto-oncogene, serine/
threonine kinase) inhibitors have been shown to improve
survival for melanomas with the BRAF gene mutation,
which account for about one-half of all cases.8587 Almost
one-half (46%) of patients with stage IV disease who
receive either chemotherapy or immunotherapy also receive
radiation therapy.14
The 5-year and 10-year relative survival rates for persons
with melanoma are 92% and 89%, respectively. About 84%
of melanomas are diagnosed at a localized stage, for which
the 5-year survival rate is 98%.
Prostate
It is estimated that there are more than 3.3 million men
living with prostate cancer in the United States, and an
additional 180,890 cases will be diagnosed in 2016. The
majority (64%) of prostate cancer survivors are over the age
of 70 years, and less than 1% are under age 50 years (Fig. 2).
The median age at diagnosis is 66 years (Fig. 3). Most prostate cancers in the United States are diagnosed by prostatespecific antigen (PSA) testing, although many expert
groups, including the American Cancer Society, have concluded that data on the efficacy of PSA screening are insufficient to recommend routine use of this test.90
Treatment and survival
Treatment options vary, depending on the extent of disease
and the risk of recurrence, as well as patient characteristics,
such as age and comorbidity, and personal preferences. Figure 9 shows primary treatment among men diagnosed during 2010 through 2012 based on SEER data [information
on the use of androgen deprivation therapy (ADT) is not
available] for all stages combined, although most (92%) of
cases are diagnosed at the localized stage. Men younger
than 65 years are most likely to be treated with radical prostatectomy (with or without radiation), whereas about onehalf of men 75 years or older do not undergo surgery or
radiation.
VOLUME 66 _ NUMBER 4 _ JULY/AUGUST 2016
281
Testis
It is estimated that there are 266,550 testicular cancer survivors in the United States, and an additional 8720 men
will be diagnosed in 2016. Testicular germ cell tumors
(TGCTs) account for approximately 97% of all testicular
cancers.62 The 2 main types of TGCTs are seminomas and
nonseminomas. Nonseminomas are more common, generally occur in men in their late teens to early 40s, and tend
to be more aggressive than seminomas. Seminomas are
slow-growing and are generally diagnosed in men in their
late 30s to early 50s.
Treatment and survival
Treatment of almost all TGCTs begins with orchiectomy.
While the most common treatment for stage I and II seminomas is surgery alone (46%), many surgical patients also
receive radiation (31%) or chemotherapy (22%) (Fig. 10).
Over the last decade, postsurgical active surveillance has
become an increasingly preferred management option for
patients with stage I seminomas, and long-term study results
support this treatment strategy.110 Stage III and IV seminomas are generally treated with surgery and chemotherapy
with or without radiation therapy (70%). Among patients
with stage I and II nonseminomas, approximately 20%
undergo retroperitoneal lymph node dissection, which is
recommended to reduce the likelihood of recurrence
(Fig. 11). Patients with stage III and IV nonseminomas are
treated with surgery and adjuvant chemotherapy, and some
require additional surgery after completion of
chemotherapy.
The 5-year, 10-year, and 15-year survival rates are all
approximately 95%. Most testicular cancers (68%) are diagnosed at a localized stage, for which the 5-year relative survival rate is 99%.
Short-term and long-term health effects
Although most men who have one healthy testicle produce
sufficient male hormones and sperm to continue sexual relations and father children, sperm banking is recommended
before treatment. Consultation about fertility risks before
treatment and referral for sperm banking as appropriate are
important in efforts to promote quality-of-life outcomes.
Retroperitoneal lymph node dissection can lead to retrograde ejaculation, making unassisted reproduction impossible. Men treated with chemotherapy have increased risks of
coronary artery disease as they age, so these patients and
FIGURE 10. Treatment Patterns (%) for Seminomatous Testicular Germ Cell Tumors by Stage, 2009 to 2013.
Chemo indicates chemotherapy (includes immunotherapy and targeted therapy); RT, radiation therapy. Source: National Cancer Data Base, 2013.
their physicians should be particularly mindful of risk factors like hyperlipidemia, hypertension, obesity, and smoking.111 Men who have bilateral tumors have both testes
removed and require lifelong testosterone supplementation.
Thyroid
It is estimated that there are 805,750 people living with a
previous thyroid cancer diagnosis in the United States, and
an additional 64,300 will be diagnosed in 2016. Thyroid
cancer is the most rapidly increasing cancer in the United
States1 and has been increasing worldwide over the past
few decades.112 Studies suggest that the rise is primarily
due to the increased incidental detection of indolent papillary tumors through widespread use of imaging.113 Accumulating awareness of this epidemic of diagnoses has
resulted in more conservative clinical practice guidelines
about when to biopsy and a subsequent stabilization of
overall incidence rates.114 However, increasing trends for
larger and follicular tumors indicate that risk factors may
also be contributing to a true increase in disease occurrence.115,116 The median age at diagnosis54 years for
males and 49 years for femalesis younger than that for
most other adult cancers (Fig. 3).
FIGURE 11. Treatment Patterns (%) for Nonseminomatous Testicular Germ Cell Tumors by Stage, 2009 to 2013.
Chemo indicates chemotherapy (includes immunotherapy and targeted therapy); RPLND, retroperitoneal lymph node dissection; RT, radiation therapy. Note
that a small proportion of patients (<1% of those with early stage disease and about 5% of those with late-stage disease) who underwent surgery also received
RT. Source: National Cancer Data Base, 2013.
VOLUME 66 _ NUMBER 4 _ JULY/AUGUST 2016
283
Urinary Bladder
It is estimated that there are 765,950 urinary bladder cancer
survivors living in the United States, and an additional
76,960 cases will be diagnosed in 2016. Bladder cancer incidence is about 4 times higher in men than in women.62
The median age at diagnosis is 73 years. More than 70% of
patients who have bladder cancer are diagnosed with
nonmuscle-invasive disease.11
Treatment and survival
For nonmuscle-invasive cancers, most patients are diagnosed and treated with transurethral resection of the bladder tumor (TURBT), which may be followed by
intravesical chemotherapy (22%) or biologic therapy with
bacillus Calmette-Guerin (29%).14 (The NCDB does not
distinguish between systemic and intravesical chemotherapy but, based on treatment guidelines, it is likely that virtually all chemotherapy is intravesical administration.)
Among patients with muscle-invasive disease, about
one-half undergo TURBT, and 39% undergo cystectomy,
with or without chemotherapy and/or radiation (Fig. 12).
TURBT followed by combined chemotherapy and
radiation therapy is as effective as cystectomy at preventing
recurrence in appropriately selected cases.121123
Chemotherapy is usually the first treatment for cancers that
284
FIGURE 13. Uterine Corpus Cancer Treatment Patterns (%) by Stage, 2013.
Chemo indicates chemotherapy (includes immunotherapy and targeted therapy); RT, radiation therapy. Source: National Cancer Data Base, 2013.
Uterine Corpus
There are an estimated 757,190 women living in the United
States with a previous diagnosis of uterine corpus cancer
and an additional 60,050 cases will be diagnosed in 2016.
Cancer of the uterine corpus is the second most prevalent
cancer among women after breast cancer. The median age
at diagnosis is 62 years (Fig. 3).
Treatment and survival
Surgery, consisting of hysterectomy (often including bilateral salpingo-oophorectomy) alone, is used to treat 69% of
patients with stage I and II disease, whereas 28% of women
receive radiation and/or chemotherapy in addition to surgery
(Fig. 13). Two-thirds of women with stage III and IV disease
undergo surgery followed by radiation and/or chemotherapy.
Clinical trials are currently assessing the most appropriate regimen of radiation and chemotherapy for women with metastatic or recurrent cancers.
The 5-year and 10-year relative survival rates for women
with uterine corpus cancer are 82% and 79%, respectively.
Most cancers (67%) are diagnosed at an early stage, usually
because of postmenopausal bleeding, for which the 5-year
survival rate is 95%. The overall 5-year survival for white
women (84%) is about 22 percentage points higher than
that for black women (62%).10
Short-term and long-term health effects
Any hysterectomy causes infertility. Bilateral oophorectomy
will cause menopause in premenopausal women, which can
lead to symptoms such as hot flashes, night sweats, atrophic
vaginitis, and osteoporosis. Long-term side effects of radiation therapy for uterine cancer can include bladder and
bowel dysfunction as well as atrophic vaginitis and stenosis.
Sexual problems are commonly reported among uterine
cancer survivors.128 Pelvic lymphadenectomy can lead to
lower extremity lymphedema, particularly for women who
also receive radiation.129
285
Conclusion
In this article, we document the continued growth of the
cancer survivor population in the United States and
describe patterns of treatment and common side effects
across the most prevalent cancers. Despite increasing
awareness of survivorship issues and the resiliency of cancer
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:730.
2. Weaver KE, Forsythe LP, Reeve BB, et al.
Mental and physical health-related quality
of life among US cancer survivors: population estimates from the 2010 National
Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012;21:2108-2117.
3. Verdecchia A, De Angelis G, Capocaccia R.
Estimation and projections of cancer prevalence from cancer registry data. Stat Med.
2002;21:3511-3526.
4. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics,
2014. CA Cancer J Clin. 2014;64:252-271.
5. Siegel R, DeSantis C, Virgo K, et al. Cancer
treatment and survivorship statistics,
2012. CA Cancer J Clin. 2012;62:220-241.
6. Mariotto AB, Yabroff KR, Feuer EJ, De
Angelis R, Brown M. Projecting the number
of patients with colorectal carcinoma by
phases of care in the US: 2000-2020. Cancer
Causes Control. 2006;17:1215-1226.
7. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ,
Brown ML. Projections of the cost of cancer
care in the United States: 2010-2020. J Natl
Cancer Inst. 2011;103:117-128.
8. Greene FL, Page DL, Fleming ID, et al, eds.
AJCC Cancer Staging Manual. 6th ed. New
York: Springer-Verlag; 2002.
9. Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL, Trotti A, eds. AJCC Cancer Stag-
286
survivors, many challenges remain. These include a fractured health care system, poor integration of survivorship
care between oncology and primary care settings, lack of
strong evidence-based guidelines for posttreatment care,
and financial and other barriers to quality care, particularly
among the medically underserved. To address these challenges, ongoing efforts to identify best practices for the
delivery of quality posttreatment cancer care are needed.
Future research should also focus on identifying the best
methods for encouraging cancer survivors to adopt and
maintain a healthy lifestyle. Models for the integration of
comprehensive care for cancer survivors, including selfmanagement, wellness and healthy lifestyle promotion, and
cancer rehabilitation, are beginning to emerge. As the evidence base grows, efforts at the individual, provider, system, and policy levels will help cancer survivors live longer
and healthier lives.
Author Contributions: Kimberly D. Miller: Conceptualization, formal analysis, investigation, writingoriginal draft, writingreview and editing, and project administration. Rebecca L. Siegel: Conceptualization, methodology,
writingreview and editing, and supervision. Chun Chieh Lin: Conceptualization, formal analysis, and writingreview and editing. Angela Mariotto:
Methodology, formal analysis, and investigation. Joan L. Kramer: Conceptualization and writingoriginal draft. Julia Rowland: Conceptualization, writing
original draft, and writingreview and editing. Kevin Stein: Writingreview
and editing. Rick Alteri: Writingreview and editing. Ahmedin Jemal:
Writingreview and editing and supervision.
16. Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph nodepositive, operable breast cancer. Cancer.
2009;115:2999-3008.
40. Pinto AC, de Azambuja E. Improving quality of life after breast cancer: dealing with
symptoms. Maturitas. 2011;70:343-348.
41. Boissel N, Sender LS. Best practices in adolescent and young adult patients with
acute lymphoblastic leukemia: a focus on
asparaginase. J Adolesc Young Adult
Oncol. 2015;4:118-128.
42. Parsons HM, Harlan LC, Seibel NL, Stevens
JL, Keegan TH. Clinical trial participation
and time to treatment among adolescents
and young adults with cancer: does age at
diagnosis or insurance make a difference?
J Clin Oncol. 2011;29:4045-4053.
43. Bleyer A. Young adult oncology: the
patients and their survival challenges. CA
Cancer J Clin. 2007;57:242-255.
44. Albritton K, Barr R, Bleyer A. The adolescence of young adult oncology. Semin
Oncol. 2009;36:478-488.
45. Armstrong GT, Oeffinger KC, Chen Y,
et al. Modifiable risk factors and major
cardiac events among adult survivors of
childhood cancer. J Clin Oncol. 2013;31:
3673-3680.
46. Hudson MM, Ness KK, Gurney JG, et al.
Clinical ascertainment of health outcomes
among adults treated for childhood cancer. JAMA. 2013;309:2371-2381.
47. Castellino SM, Ullrich NJ, Whelen MJ,
Lange BJ. Developing interventions for
cancer-related cognitive dysfunction in
childhood cancer survivors [serial online].
J Natl Cancer Inst. 2014;106. pii:dju186.
48. Barton SE, Najita JS, Ginsburg ES, et al.
Infertility, infertility treatment, and
achievement of pregnancy in female survivors of childhood cancer: a report from
the Childhood Cancer Survivor Study
cohort. Lancet Oncol. 2013;14:873-881.
49. Wasilewski-Masker
K,
Seidel
KD,
Leisenring W, et al. Male infertility in
long-term survivors of pediatric cancer: a
report from the Childhood Cancer Survivor
Study. J Cancer Surviv. 2014;8:437-447.
50. Barr RD, Ferrari A, Ries L, Whelan J,
Bleyer WA. Cancer in adolescents and
young adults: a narrative review of the
current status and a view of the future
[published online ahead of print March
21, 2016]. JAMA Pediatr. doi: 10.1002/
jamapediatrics.2015.4689.
51. Surveillance, Epidemiology, and End
Results (SEER) Program. SEER-Medicare
linked database 20062010. Bethesda,
MD: National Cancer Institute, Division of
Cancer Control and Population Sciences,
Applied Research Program, Health Services and Economics Branch; 2013.
287
288
123. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation
plus paclitaxel-cisplatin or fluorouracilcisplatin with selective bladder preservation and adjuvant chemotherapy for
patients with muscle invasive bladder cancer (RTOG 0233): a randomised multi-
289